Sarepta Therapeutics Securities Class Action Lawsuit

Rosen Law Firm reminds investors of securities of Sarepta Therapeutics, Inc. between June 22, 2023, and June 24, 2025, of the important August 25, 2025, lead plaintiff deadline. The class action lawsuit alleges that Sarepta made false and misleading statements about its prescription gene therapy, ELEVIDYS, posing significant safety risks to patients, failing to detect severe side effects, and attracting regulatory scrutiny.

Key Takeaways:

• The class action lawsuit covers investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025.
• The lawsuit claims that Sarepta made false and misleading statements about ELEVIDYS, a prescription gene therapy for Duchenne muscular dystrophy.
• Defendants allegedly failed to disclose significant safety risks to patients, severe side effects, and regulatory scrutiny.
• The class action lawsuit seeks compensation for investors who suffered damages due to Sarepta's false and misleading statements.
• The lead plaintiff deadline is August 25, 2025.
• Rosen Law Firm, a global investor rights law firm, represents investors throughout the globe and has a track record of success in securities class actions.

Statistics:

• The class period is from June 22, 2023, to June 24, 2025.
• The lead plaintiff deadline is August 25, 2025.
• Rosen Law Firm has recovered hundreds of millions of dollars for investors in securities class actions.
• In 2019, the firm secured over $438 million for investors.
• In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar.

Sources:

• Newsfile Corp. (August 5, 2025)
• Rosen Law Firm ( https://rosenlegal.com/submit-form/?case_id=20094 )